Coronavirus Scientific Advisory Board

HeartBeam Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Data Management, Health, Medical Devices, Technology, Health Technology, Software, Cardiology, Sale, Webcast, Senior, Regulatory affairs, CFO, Boston Scientific, Common stock, Research, Algorithm, FDA, Electrophysiology, SAB, Coronary occlusion, Trial of the century, Splenic infarction, Arrhythmia, Doctor of Philosophy, Patent, United States patent law, AI, Coronavirus Scientific Advisory Board, Physician, Innovation, Medical device, Pharmaceutical industry, Cryptocurrency, Video game, MD

“During the third quarter of 2023 we significantly enhanced the HeartBeam team, continued to make steady progress toward upcoming clinical and regulatory milestones, and validated the potential of our VECG technology platform,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam.

Key Points: 
  • “During the third quarter of 2023 we significantly enhanced the HeartBeam team, continued to make steady progress toward upcoming clinical and regulatory milestones, and validated the potential of our VECG technology platform,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam.
  • Research and development expenses for the third quarter of 2023 were $1.6 million, compared to $1.6 million for the third quarter of 2022.
  • General and administrative expenses for the third quarter of 2023 were $2.1 million compared to $2.0 million for the third quarter of 2022.
  • Net loss for the third quarter of 2023 was $3.5 million, compared to a net loss of $3.6 million for the third quarter of 2022.

Avstera Therapeutics Announces FDA Clearance of IND Application for AVS100, a Novel Highly Selective HDAC6 Inhibitor Targeting Solid Tumors

Retrieved on: 
Monday, December 18, 2023
Georgetown University, Tumor-associated macrophage, AMES, Research, GLP, Safety, Therapy, Incidence, RECIST, Toxicology, IND, Risk, Macrophage, Patient, FIH, PFS, MD Anderson Cancer Center, U.S. FDA, FDA, Pembrolizumab, Animal, ICB, SAB, Pharmacokinetics, Marketing, Investigational New Drug, FAAAS, Progression-free survival, ORR, MD, Cancer, MTD, Phase, Doctor of Philosophy, HDAC6, Biomarker, Infrared spectroscopy correlation table, Immunotherapy, Coronavirus Scientific Advisory Board, Neoplasm, Rat, Dog, Government, Pharmaceutical industry, Medicine

AVS100 is a novel, orally bioavailable selective HDAC6i targeting locally advanced or metastatic solid tumors, including in combination with pembrolizumab.

Key Points: 
  • AVS100 is a novel, orally bioavailable selective HDAC6i targeting locally advanced or metastatic solid tumors, including in combination with pembrolizumab.
  • "The FDA clearance of our IND for AVS100 marks an amazing step for our company towards the fulfillment of our mission.
  • "FDA clearance of our IND for AVS100 represents a significant milestone for Avstera's mission in providing state of the art oncological agents to tackle solid tumors.
  • Undoubtedly, the IND approval of AVS100 selective HDAC6 inhibitor will open new opportunities to potentially enhance response rates for patients."

4Moving Biotech forms its Scientific Advisory Board of World-Renowned Knee Osteoarthritis Experts

Retrieved on: 
Friday, November 10, 2023
Research, Hospitals, Clinical Trials, Biotechnology, Other Health, Managed Care, Health, Pharmaceutical, Science, Orthopedic surgery, Cell biology, Hospital, University of Leeds, Multimedia, Shanghai Sixth People's Hospital, University, Trial of the century, Physiology, CMO, Coronavirus Scientific Advisory Board, Radiology, Medical school, Paracelsus Medical University, Microsurgeon, Pharmaceutical industry, Anatomy, Biostatistics, Medicine, Boston

4Moving Biotech, a subsidiary of 4P-Pharma, announces establishing an international Scientific Advisory Board in anticipation of its knee osteoarthritis drug candidate's phase 2b clinical trial.

Key Points: 
  • 4Moving Biotech, a subsidiary of 4P-Pharma, announces establishing an international Scientific Advisory Board in anticipation of its knee osteoarthritis drug candidate's phase 2b clinical trial.
  • Professor Francis Berenbaum, CMO of 4Moving Biotech, will lead the work of this scientific advisory board.
  • The Scientific Advisory Board will bring deep knowledge and experience from clinical research, academia, and industry to better serve people suffering from knee osteoarthritis.
  • 4Moving Biotech has responded to this challenge with an innovative research program to explore the potential of intra-articular GLP-1 analogs for knee osteoarthritis treatment.

Digital Health Startup CARI Health Establishes Advisory Board

Retrieved on: 
Thursday, November 9, 2023
Wearables, Mobile Technology, Technology, Mental Health, Medical Devices, Health Technology, Professional Services, Start-Up, Health, Pharmaceutical, Johns Hopkins University, Medicine, Psychiatry, Addiction psychiatry, Methadone, Patient, Coronavirus Scientific Advisory Board, Digital, CARI, Behavioural sciences, MD, Advisory board, UCSD, Medical device, Dentistry, Pharmaceutical industry

Digital health company CARI Health forms Advisory Board to support development of its wearable remote medication monitoring device .

Key Points: 
  • Digital health company CARI Health forms Advisory Board to support development of its wearable remote medication monitoring device .
  • CARI Health intends to enable clinicians to view patient medication levels remotely in real time, ensuring correct dosages of prescribed medications.
  • “We are honored to have these outstanding professionals on the CARI Health Advisory Board.
  • CARI Health Advisory Board members include:
    Carla Marienfeld, MD, DFAPA, FASAM, board-certified, psychiatry, addiction psychiatry and addition medicine; Clinical Professor, UCSD
    Ken Stoller, MD, Professor of Clinical Psychiatry and Behavioral Sciences at Johns Hopkins University; Medical Director Behavioral Health for Johns Hopkins Health Plan
    “The promise of methadone patients being able to demonstrate compliance remotely, without daily clinic visits, is what attracted me to CARI Health,” said Patient Advocate Brenda Davis.

Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform

Retrieved on: 
Tuesday, December 12, 2023
Research, Immune system, Engineering, Therapy, Bone marrow, Kyoto University, Biotechnology, Patient, Cell, Regenerative medicine, Autoimmune disease, IPSC, University, University of California, Coronavirus Scientific Advisory Board, Global Partnership for Education, FTI, Pharmaceutical industry, Vaccine, Ninja, Katana

SAN FRANCISCO and KYOTO, Japan, Dec. 12, 2023 /PRNewswire/ -- Shinobi Therapeutics (Shinobi), the biotechnology company developing a new class of immune evasive iPS-T cell therapies, today announced that it has closed a $51 million Series A financing. The oversubscribed round was led by EQT Life Sciences, F-Prime Capital and Eight Roads Ventures Japan, with participation from Astellas Venture Management, Fast Track Initiative (FTI), JIC Venture Growth Investments, and D3 LLC. Shinobi will use the funds to advance its 'Katana' iPS-T cell therapy platform and progress its first program to treat GPC3+ solid tumor cancers toward the clinic.

Key Points: 
  • Shinobi will use the funds to advance its 'Katana' iPS-T cell therapy platform and progress its first program to treat GPC3+ solid tumor cancers toward the clinic.
  • "Having led several cell therapy programs at other global companies, I've never encountered a technology platform that is capable of advancing the field as dramatically as this."
  • "Shinobi stands alone in the growing cell therapy field by engineering the most comprehensive immune evasion technology directly into its cell products," said Robert Weisskoff, Ph.D, Partner at F-Prime Capital.
  • "Shinobi's hypoimmune technology opens the door to a broader pipeline of off-the-shelf cell therapies far beyond T cells and oncology.

Landmark Research From Maven Clinic Finds Virtual Doula Care Improves Birth Experiences and Reduces C-sections at Rates Comparable to In-Person Doula Support

Retrieved on: 
Wednesday, December 6, 2023
Woman, Black, Research, NICU, Blue Cross, University, Literature, Gynaecology, Learning, History, Pregnancy, Consultant, Mother, Lactation, Digital technology, Mental health, Coronavirus Scientific Advisory Board, Education, Nursing, Birth control, Medical device, Maven, Obstetrics, Health

NEW YORK, Dec. 6, 2023 /PRNewswire/ -- Maven Clinic, the world's largest virtual clinic for women and families, today published a first-of-its-kind peer-reviewed study in Obstetrics and Gynecology examining the impact of virtual doula care on birth experiences and outcomes. The research, drawing on data from nearly 9,000 Maven members, found that virtual doula care improves birth experiences and reduces the odds of C-section at rates comparable to in-person doula care, with the greatest impact seen among Black members. The findings demonstrate how digital health platforms can play a critical role in increasing access to quality care, ultimately promoting equitable maternal health outcomes and driving down healthcare costs.

Key Points: 
  • The research, drawing on data from nearly 9,000 Maven members, found that virtual doula care improves birth experiences and reduces the odds of C-section at rates comparable to in-person doula care, with the greatest impact seen among Black members.
  • Despite research showing that doulas can improve maternal health outcomes and reduce disparities in care, only 6% of births in the United States are supported by a doula.
  • Doulas can play an important role in a pregnancy care team, providing continuous support, education and advocacy before birth, during labor and throughout the postpartum period.
  • Significant barriers to accessing doula care persist, and far too often care is unavailable or unaffordable for the communities that could benefit from it most.

Marengo Therapeutics Announces Publication Describing STAR0602, a Novel, TCR-Targeting Cancer Immunotherapy, in Science Translational Medicine

Retrieved on: 
Wednesday, December 6, 2023
University of Pennsylvania, Translation, TCR, Immune system, Therapy, Toxicity, Phenotype, National Cancer Institute, Risk, Clinical trial, NCI, Chairperson, Epitope, Patient, Pharmacology, Science Translational Medicine, Immunology, NIH, University, Cancer, Coronavirus Scientific Advisory Board, Bangladesh Technical Education Board, Biology, STAR, Vaccine

Lead authors on the publication are Jonathan Hsu, M.Sc., Principal Scientist at Marengo, and Renee Donahue, from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).

Key Points: 
  • Lead authors on the publication are Jonathan Hsu, M.Sc., Principal Scientist at Marengo, and Renee Donahue, from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
  • "The comprehensive data reported in our Science Translational Medicine publication underscore the potential of Marengo's broad STAR platform to target and activate subsets of T cells expressing different beta chain TCRs," said Andrew Bayliffe, Ph.D., Chief Scientific Officer of Marengo.
  • said James Gulley, M.D., Ph.D., Co-Director of the Center for Immuno-Oncology at the NCI and Clinical Director, NCI.
  • "Having a new strategy to activate the immune system for these patients is important and currently an unmet need.

Lung Cancer Research Foundation and the International Association for the Study of Lung Cancer (IASLC) Announce New Research Partnership

Retrieved on: 
Tuesday, December 5, 2023
Research, Organization, NTRK, International Association, TKI, Patient, ROS1, Death, FDA, Neoplasm, Lung cancer, Science of team science, Request, BRAF, HER2, Cancer, MET, Partnership, RET, Coronavirus Scientific Advisory Board, EGFR, Estate (law), Pharmaceutical industry

NEW YORK, Dec. 5, 2023 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) and the International Association for the Study of Lung Cancer (IASLC) today announced a new research partnership, titled IASLC - LCRF Team Science Research Grant on the Next Step in the Cure of Oncogene-Driven Lung Cancers.

Key Points: 
  • NEW YORK, Dec. 5, 2023 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) and the International Association for the Study of Lung Cancer (IASLC) today announced a new research partnership, titled IASLC - LCRF Team Science Research Grant on the Next Step in the Cure of Oncogene-Driven Lung Cancers.
  • Lung cancer is responsible for more deaths worldwide than any other cancer, accounting for an estimated 130,180 deaths annually in the United States alone.
  • "Resistance in oncogene-driven lung cancers is a frustrating inevitability for these patients," says Dr. Antoinette Wozniak, Chief Scientific Officer for LCRF.
  • "We're pleased to be collaborating with LCRF to create this Team Science award to work on curing oncogenic-driven lung cancers."

Lupus Research Alliance Gala Raises Millions for Research to Transform Treatment

Retrieved on: 
Tuesday, November 21, 2023
Executive producer, Sony Music, Woman, Research, Host, Tamron Hall, Special, Hope, Prevalence, Disease, Hospital, LRA, Hospital for Special Surgery, Patient, Sullivan & Cromwell, Oliver Cromwell, Autoimmune disease, MBA, MD, Lupus, Empire, Coronavirus Scientific Advisory Board, David Johnson (company director), Empire State Building, Lupus Research Alliance, Human, Bloomberg L.P., Interior design, Management

NEW YORK, Nov. 21, 2023 /PRNewswire/ -- This year's Lupus Research Alliance (LRA) Breaking Through Gala raised $2 million for lupus research and brought the hope of tremendous progress that's improving lupus treatment while driving to a cure. The annual celebration began with a powerhouse performance and moving tribute to lupus warriors by multi-talented pianist, composer, producer, and Sony Music recording artist Chloe Flower. Emmy Award-winning TV Host and Executive Producer, Tamron Hall, brought her refreshing and relatable voice to emcee the night's program with warmth and compassion.

Key Points: 
  • The annual celebration began with a powerhouse performance and moving tribute to lupus warriors by multi-talented pianist, composer, producer, and Sony Music recording artist Chloe Flower.
  • "Lupus is a complex autoimmune disease that can take years to get diagnosed and disproportionately affects women of color in prevalence and severity.
  • Being here to help raise awareness and funds for the finest research is how we can best help improve the lives of people with lupus," explained Hall.
  • A star of the event, the iconic Empire State Building, brightened the city Sunday night, highlighting the importance of lupus research by lighting up NYC's skyline in the colors of lupus research awareness – purple and red.

Owl Therapeutics Enters a Strategic Clinical Collaboration With Abliva to Advance NeuroSTAT® (OWL-1410) for Traumatic Brain Injury

Retrieved on: 
Friday, November 17, 2023
Mitochondrial disease, Brain, Research, SAN, Entrepreneurship, Therapy, TBI, ODD, NADH, IND, Disease, Traumatic brain injury, Long-term care, Patient, Multimedia, Rehabilitation, Blood, Mitochondrion, Owl, Diagnosis, Neurodegenerative disease, Doctor of Philosophy, Biomarker, Coronavirus Scientific Advisory Board, Fast Track, Hospital, Accident, Public, Drug development, Injury, Pharmaceutical industry, Medical device, Nasdaq Stockholm

The collaboration agreement provides Owl Therapeutics with a global license to develop, manufacture, and commercialize NeuroSTAT®.

Key Points: 
  • The collaboration agreement provides Owl Therapeutics with a global license to develop, manufacture, and commercialize NeuroSTAT®.
  • "Abliva stands out as an exceptional partner for Owl Therapeutics, and we are excited to join forces in our collective commitment to advance NeuroSTAT® (OWL-1410)," said William E. Haskins, PhD, Co-Founder of Owl Therapeutics and Chief Executive Officer of Gryphon Bio.
  • "We are thrilled to focus our team's scientific, clinical, and business experience on this potentially game-changing treatment for military and civilian TBI patients."
  • Owl Therapeutics, a wholly-owned subsidiary of Gryphon Bio, is a clinical-stage biopharmaceutical company created to develop diagnostic-powered therapeutics for traumatic brain injury (TBI) and brain health.